A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
Key facts
- Where
- Canton, Chicago, Dallas, Fremont, Hot Springs, Irvine, Louisville, Miramar, Pasadena, Portland, Scottsdale, South Jordan, and Webster, United StatesSee the 13 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06625177, who can take part
Where in United States
- Hamzavi DermatologyCanton, United StatesTaking people
- MetroMed Clinical TrialsChicago, United StatesNo longer taking part
- Dermatology Treatment & Research CenterDallas, United StatesTaking people
- Center For Dermatology Clinical Research, Inc.Fremont, United StatesTaking people
- Burke Pharmaceutical ResearchHot Springs, United StatesTaking people
- University of CA IrvineIrvine, United StatesNo longer taking part
- DS Research of KentuckyLouisville, United StatesTaking people
- Watson Therapeutics Inc. (WTI), USAMiramar, United StatesTaking people
- Pasadena Clinical TrialsPasadena, United StatesNo longer taking part
- Oregon Dermatology and Research CenterPortland, United StatesTaking people
- Scottsdale Clinical ResearchScottsdale, United StatesNo longer taking part
- Jordan Valley DermatologySouth Jordan, United StatesNo longer taking part
- Center for Clinical Studies, LTD. LLPWebster, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Teva Branded Pharmaceutical Products R&D LLC
- Trial code
- NCT06625177
- Record updated
- 29 October 2026
- Original description
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.Read full original descriptionShow less
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.
Inclusion: The participant has a diagnosis of active or stable vitiligo for at least 3 months; The participant has a body mass index (BMI) within the range of 18.5 to 40.0 kg/m2; A female participant is eligible if she is not pregnant or breastfeeding AND is a woman of nonchildbearing potential OR is a women of childbearing potential using a contraceptive method that is highly effective AND agrees not to donate eggs for the purpose of reproduction for the required period; A male participant is eligible if he agrees to refrain from donating sperm PLUS remain abstinent from heterosexual intercourse OR use a male condom with a female partner for the required period; The participant is capable of giving signed, informed consent; The participant agrees to discontinue all agents and procedures used to treat vitiligo during the treatment period in the trial; If receiving permitted concomitant medications for any reason other than vitiligo, the participant must be on a stable regimen,; The participant must agree to avoid prolonged exposure to the sun, must use sunscreen, and must not use tanning booths, sun lamps, or other ultraviolet light sources; NOTE - Additional criteria apply, please contact the investigator for more information.
Exclusion: The participant suffers from vitiligo induced by exposure to chemicals or immunotherapy known to induce vitiligo; The participant has other autoimmune diseases for which systemic immunotherapy is or may be warranted; The participant has current or history of malignancy or treatment of malignancy in the last 5 years, excluding fully-treated basal cell carcinoma; Infectious disease; The participant has a history of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo. After 2 or more years since last melanocyte-keratinocyte transplantation procedure, the participants may be included in the trial; The participant has current or history of alcohol or other substance abuse; NOTE- Additional criteria apply, please contact the investigator for more information; The participant has donated or received any blood or blood products (white blood cells, platelets, etc) within the 60 days prior to screening or has donated blood or blood products on 2 or more occasions within the 6 months prior to IMP administration, or has donated plasma within 7 days before the screening visit, or has planned donations during the trial; The participant has used skin bleaching treatments for past treatment of vitiligo or other pigmented areas.